Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by toniZ1on Nov 16, 2022 1:58pm
69 Views
Post# 35104195

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Buy Replicel Shares

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Buy Replicel Sharesyes, the dermal injector is not much worth if it ever gets released. Others said its not the injector that brings the money its the injectables - haha, think replicel has none so far ;-)

From my point of view the only thing that counts is Shiseido. In the first study they did, they applied a single injection and showed a single hair, many people got disappointed but I think that was the proof that it works. It simliar to a hair transplant but instead of implantating hair grafts they inject cells, so for each new hair you probably need one injection... Shiseido did not start the 2nd trail if they did have the impression that it won't work. 

Due to the dispute with Replicel they probably wanted to wait for them to go bancrupt to pick up the assets for cheap. The arbitration and the money of Andrew hopefully avoid this scenario and if so a buy-out price around 500m is more than likely...

So, still here waiting for the showdown... should not be far away anymore...


<< Previous
Bullboard Posts
Next >>